MDR-TB treatment in prison setting Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007
New-immigrant screening for latent tuberculosis infection: Reasons for non-treatment Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
Outcomes of MDR-TB treatment in penitentiary medical setting Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment of latent tuberculosis in immigrants from Somalia: Case-monitoring and adherence Source: Annual Congress 2010 - Tuberculosis in special populations Year: 2010
MDR TB treatment in prison Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002
Screening migrants for tuberculosis and latent TB infection: the reward will come later Source: Eur Respir J, 54 (4) 1901719; 10.1183/13993003.01719-2019 Year: 2019
Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013
Results of the treatment of relapses of tuberculosis by DOTS method Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia Source: ERJ Open Res, 6 (1) 00030-2019; 10.1183/23120541.00030-2019 Year: 2020
Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Population of bacteria in treatment of patients with tuberculosis by DOTS method Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001
MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014
Reasons for failure to control the London-based isoniazid outbreak of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 438s Year: 2004
Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme Source: Annual Congress 2010 - Tuberculosis epidemiology Year: 2010